Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN950266 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-ADAM Metallopeptidase Domain 19 (Adam19) (AA 215-245), (Middle Region) antibody
- Antibody type
- Polyclonal
- Description
- Saturated Ammonium Sulfate (SAS) precipitation
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- AA 215-245, Middle Region
- Vial size
- 0.4 mL
- Storage
- Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
- Handling
- Avoid repeated freezing and thawing.
Submitted references Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function.
New sequence variants associated with bone mineral density.
Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer.
ADAM19 is tightly associated with constitutive Alzheimer's disease APP alpha-secretase in A172 cells.
Upregulation of ADAM19 in chronic allograft nephropathy.
Intracellular activation of human adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites.
Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, Franceschini N, van Durme YM, Chen TH, Barr RG, Schabath MB, Couper DJ, Brusselle GG, Psaty BM, van Duijn CM, Rotter JI, Uitterlinden AG, Hofman A, Punjabi NM, Rivadeneira F, Morrison AC, Enright PL, North KE, Heckbert SR, Lumley T, Stricker BH, O'Connor GT, London SJ
Nature genetics 2010 Jan;42(1):45-52
Nature genetics 2010 Jan;42(1):45-52
New sequence variants associated with bone mineral density.
Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Snorradóttir S, Center JR, Nguyen TV, Alexandersen P, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K
Nature genetics 2009 Jan;41(1):15-7
Nature genetics 2009 Jan;41(1):15-7
Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer.
Chan MW, Huang YW, Hartman-Frey C, Kuo CT, Deatherage D, Qin H, Cheng AS, Yan PS, Davuluri RV, Huang TH, Nephew KP, Lin HJ
Neoplasia (New York, N.Y.) 2008 Sep;10(9):908-19
Neoplasia (New York, N.Y.) 2008 Sep;10(9):908-19
ADAM19 is tightly associated with constitutive Alzheimer's disease APP alpha-secretase in A172 cells.
Tanabe C, Hotoda N, Sasagawa N, Sehara-Fujisawa A, Maruyama K, Ishiura S
Biochemical and biophysical research communications 2007 Jan 5;352(1):111-7
Biochemical and biophysical research communications 2007 Jan 5;352(1):111-7
Upregulation of ADAM19 in chronic allograft nephropathy.
Melenhorst WB, van den Heuvel MC, Stegeman CA, van der Leij J, Huitema S, van den Berg A, van Goor H
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006 Jul;6(7):1673-81
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006 Jul;6(7):1673-81
Intracellular activation of human adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites.
Kang T, Zhao YG, Pei D, Sucic JF, Sang QX
The Journal of biological chemistry 2002 Jul 12;277(28):25583-91
The Journal of biological chemistry 2002 Jul 12;277(28):25583-91
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- FACS
